Beam Therapeutics Inc.

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through its pioneering base editing platform. This technology enables precise single-nucleotide changes in DNA without double-strand breaks, targeting serious genetic diseases. Key programs include BEAM-101, a base editor for sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle formulation for alpha-1 antitrypsin deficiency; and BEAM-301 for glycogen storage disease type Ia. The company also advances BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy integration, alongside liver-targeted initiatives like BEAM-304 for phenylketonuria. Beam Therapeutics employs a suite of delivery modalities, including electroporation, nonviral, and viral approaches, to support in vivo and ex vivo editing. Operating in the gene therapy and genome editing sector, it addresses unmet needs in hematology and liver genetic disorders. Founded in 2017 and headquartered in Cambridge, Massachusetts, with a manufacturing facility in Research Triangle Park, North Carolina, Beam Therapeutics focuses on innovative solutions for patients with debilitating conditions.